Minh Sang
Doan
a,
Eun Jae
Park
b,
Duong Tien
Anh
a,
Do Thi Mai
Dung
a,
Le
Quang-Bao
a,
Pham-The
Hai
a,
Dao Thi Kim
Oanh
a,
Truong Thanh
Tung
cd,
Ik Ho
Na
b,
Joo Hee
Kwon
e,
Jong Soon
Kang
e,
Sang-Bae
Han
*b,
Dinh Thi Thanh
Hai
a and
Nguyen-Hai
Nam
*a
aDepartment of Pharmaceutical Chemistry, Hanoi University of Pharmacy, 13-15 Le Thanh Tong, Hoan Kiem, Hanoi 10000, Vietnam. E-mail: namnh@hup.edu.vn
bCollege of Pharmacy, Chungbuk National University, 194-31, Osongsaengmyung-1, Heungdeok, Cheongju, Chungbuk 28160, Republic of Korea. E-mail: shan@chungbuk.ac.kr
cPHENIKAA Institute for Advanced Study (PIAS), Phenikaa University, Hanoi 12116, Vietnam
dFaculty of Pharmacy, PHENIKAA University, Hanoi 12116, Vietnam
eKorea Research Institute of Bioscience and Biotechnology, Cheongju, Chungbuk 28160, Republic of Korea
First published on 21st December 2023
Correction for ‘Novel (E)-3-(1-substituted-1H-indazol-5-yl)-N-hydroxypropenamides as histone deacetylase inhibitors: design, synthesis and structure–activity relationships’ by Minh Sang Doan et al., New J. Chem., 2023, 47, 4478–4490, https://doi.org/10.1039/D2NJ04894A.
We acknowledge the principal financial supports from the National Foundation for Science and Technology of Vietnam (NAFOSTED, grant number 104.01-2020.19). The work was also partly supported by a grant funded by the Korean Government (NRF, grant number 2017R1A5A2015541 and 2020R1A2C2004200). DTA was funded by the Postdoctoral Scholarship Programme of Vingroup Innovation Foundation (VINIF), code VINIF.2022.STS.55.
The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.
This journal is © The Royal Society of Chemistry and the Centre National de la Recherche Scientifique 2024 |